Marmesin is a coumarin originally isolated from the mature bark of A. marmelos.1 Marmesin decreases proliferation and cell invasion induced by fetal bovine serum (FBS) in H1299 non-small cell lung cancer cells (NSCLCs) when used at a concentration of 10 ?M.2 It decreases VEGF secretion in A549 and H1299 cells and inhibits capillary-like structure formation by human umbilical vein endothelial cells (HUVECs). Marmesin also decreases proliferation of U937 human leukemia cells (IC50 = 40 ?M).3 It halts the cell cycle at the G2/M phase, increases the ratio of Bax to Bcl-2 protein, induces apoptosis, and inhibits cell migration. Marmesin reduces tumor growth in a U937 mouse xenograft model when administered at a dose of 30 mg/kg.
1.Chatterjee, A., and Mitra, S.S.On the constitution of the active principles isolated from the mature bark of Aegle marmelos, Corre?J. Am. Chem. Soc.71(2)606-609(1949) 2.Kim, J.H., Kim, M.S., Lee, B.H., et al.Marmesin-mediated suppression of VEGF/VEGFR and integrin β1 expression: Its implication in non-small cell lung cancer cell responses and tumor angiogenesisOncol. Rep.37(1)91-97(2017) 3.Dong, L., Xu, W.W., Li, H., et al.In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrial-mediated apoptosis, cell cycle arrest, and inhibition of cancer cell migrationOncol. Rep.39(2)597-602(2018)